# Elite Pharmaceuticals Inc: overview ELTP · OTC · CIK 1053369 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Mar 31 Pages: [Overview](/companies/eltp.md) · [Financials](/companies/eltp/financials.md) · [Filings](/companies/eltp/filings.md) · [Insiders](/companies/eltp/insiders.md) Latest reported revenue: [$32.4m](/filings/0001493152-26-037752.md) for Q1 FY2027, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001493152-26-037752). ## Last eight quarters | Line item | Unit | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [18.9](/filings/0001493152-25-023477.md) | [14.4](/filings/0001493152-26-007104.md) | [32.0 d](/filings/0001493152-26-031070.md) | [40.2](/filings/0001493152-26-037752.md) | [36.3](/filings/0001493152-25-023477.md) | [31.6](/filings/0001493152-26-007104.md) | [40.7 d](/filings/0001493152-26-031070.md) | [32.4](/filings/0001493152-26-037752.md) | | Gross margin | % | [43.4%](/filings/0001493152-25-023477.md) | [42.6%](/filings/0001493152-26-007104.md) | [54.1% d](/filings/0001493152-26-031070.md) | [67.7%](/filings/0001493152-26-037752.md) | [38.7%](/filings/0001493152-25-023477.md) | [41.0%](/filings/0001493152-26-007104.md) | [51.0% d](/filings/0001493152-26-031070.md) | [41.7%](/filings/0001493152-26-037752.md) | | Operating margin | % | [18.5%](/filings/0001493152-25-023477.md) | [7.6%](/filings/0001493152-26-007104.md) | [34.9% d](/filings/0001493152-26-031070.md) | [54.0%](/filings/0001493152-26-037752.md) | [22.6%](/filings/0001493152-25-023477.md) | [28.5%](/filings/0001493152-26-007104.md) | [25.0% d](/filings/0001493152-26-031070.md) | [23.3%](/filings/0001493152-26-037752.md) | | Net margin | % | [(58.5%)](/filings/0001493152-26-007104.md) | [(75.8%)](/filings/0001493152-26-007104.md) | [53.1% d](/filings/0001493152-26-031070.md) | [(14.6%)](/filings/0001493152-26-037752.md) | [37.7%](/filings/0001493152-26-007104.md) | [58.9%](/filings/0001493152-26-007104.md) | [45.3% d](/filings/0001493152-26-031070.md) | [18.3%](/filings/0001493152-26-037752.md) | | Diluted EPS | $ per share | [(0.01)](/filings/0001493152-25-023477.md) | [(0.01)](/filings/0001493152-26-007104.md) | not reported | [(0.01)](/filings/0001493152-26-037752.md) | [0.01](/filings/0001493152-25-023477.md) | [0.01](/filings/0001493152-26-007104.md) | not reported | [0.01](/filings/0001493152-26-037752.md) | | Free cash flow | $m | [1.4 d](/filings/0001493152-25-023477.md) | [(1.1) d](/filings/0001493152-26-007104.md) | [3.2 d](/filings/0001493152-26-031070.md) | [14.6](/filings/0001493152-26-037752.md) | [5.0 d](/filings/0001493152-25-023477.md) | [(5.5) d](/filings/0001493152-26-007104.md) | [8.7 d](/filings/0001493152-26-031070.md) | [9.3](/filings/0001493152-26-037752.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-03-31) | FY2023 (2023-03-31) | FY2024 (2024-03-31) | FY2025 (2025-03-31) | FY2026 (2026-03-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [32.3](/filings/0001493152-23-022936.md) | [34.2](/filings/0001493152-24-025829.md) | [56.6](/filings/0001641172-25-017134.md) | [84.0](/filings/0001493152-26-031070.md) | [149](/filings/0001493152-26-031070.md) | | Gross margin | % | [45.9%](/filings/0001493152-23-022936.md) | [48.6%](/filings/0001493152-24-025829.md) | [46.5%](/filings/0001641172-25-017134.md) | [47.7%](/filings/0001493152-26-031070.md) | [50.4%](/filings/0001493152-26-031070.md) | | Operating margin | % | [15.7%](/filings/0001493152-23-022936.md) | [10.8%](/filings/0001493152-24-025829.md) | [19.1%](/filings/0001641172-25-017134.md) | [23.3%](/filings/0001493152-26-031070.md) | [33.0%](/filings/0001493152-26-031070.md) | | Net margin | % | [27.6%](/filings/0001493152-23-022936.md) | [10.4%](/filings/0001493152-24-025829.md) | [35.5%](/filings/0001641172-25-017134.md) | [(5.1%)](/filings/0001493152-26-031070.md) | [30.1%](/filings/0001493152-26-031070.md) | | Diluted EPS | $ per share | [0.01](/filings/0001493152-23-022936.md) | [0.00](/filings/0001493152-24-025829.md) | [0.02](/filings/0001641172-25-017134.md) | [0.00](/filings/0001493152-26-031070.md) | [0.03](/filings/0001493152-26-031070.md) | | Free cash flow | $m | [6.0](/filings/0001493152-23-022936.md) | [(2.4)](/filings/0001493152-24-025829.md) | [(4.0)](/filings/0001641172-25-017134.md) | [5.8](/filings/0001493152-26-031070.md) | [22.8](/filings/0001493152-26-031070.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/eltp/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [KELLEHER FINANCIAL ADVISORS](/funds/1507971.md) | 2026-06-30 | $365 | 1,000 | | Added +500 | ## Recent filings [All 828 filings](/companies/eltp/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-13 | 20:17 ET | [8-K](/filings/0001493152-26-037787.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-037787 | | 2026-08-13 | 20:06 ET | [10-Q](/filings/0001493152-26-037752.md) | Quarterly report, period 2026-06-30 | 0001493152-26-037752 | | 2026-08-11 | 00:16 ET | [8-K/A](/filings/0001493152-26-036936.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-036936 | | 2026-08-10 | 21:07 ET | [8-K](/filings/0001493152-26-036905.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-036905 | | 2026-08-04 | 11:05 ET | [8-K](/filings/0001493152-26-035922.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-035922 | | 2026-06-29 | 20:51 ET | [8-K](/filings/0001493152-26-031103.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-031103 | | 2026-06-29 | 20:05 ET | [10-K](/filings/0001493152-26-031070.md) | Annual report, period 2026-03-31 | 0001493152-26-031070 | | 2026-06-23 | 11:02 ET | [8-K](/filings/0001493152-26-029700.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-029700 | | 2026-06-15 | 11:02 ET | [8-K](/filings/0001493152-26-028610.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-028610 | | 2026-06-01 | 11:00 ET | [8-K](/filings/0001493152-26-026519.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-026519 | ## Latest annual report [Form 10-K for the fiscal year ended Mar 31, 2026](/filings/0001493152-26-031070.md), filed Jun 29, 2026. ## Forecast league Q2 FY2027, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/cfc4ec9f-f13e-4b80-8e3c-4556d38f11a6) ## About the filer - CIK: 1053369 - Tickers: ELTP - Exchange: OTC - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: NJ - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:31 ET. No prices; not investment advice.